DK1765397T3 - Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR) - Google Patents
Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)Info
- Publication number
- DK1765397T3 DK1765397T3 DK05754219.3T DK05754219T DK1765397T3 DK 1765397 T3 DK1765397 T3 DK 1765397T3 DK 05754219 T DK05754219 T DK 05754219T DK 1765397 T3 DK1765397 T3 DK 1765397T3
- Authority
- DK
- Denmark
- Prior art keywords
- upar
- upa
- urokinase
- bind
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57389604P | 2004-05-25 | 2004-05-25 | |
PCT/US2005/018322 WO2005116077A2 (en) | 2004-05-25 | 2005-05-25 | LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1765397T3 true DK1765397T3 (da) | 2013-02-04 |
Family
ID=35451457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05754219.3T DK1765397T3 (da) | 2004-05-25 | 2005-05-25 | Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR) |
Country Status (16)
Country | Link |
---|---|
US (1) | US8101726B2 (da) |
EP (1) | EP1765397B1 (da) |
JP (1) | JP4890449B2 (da) |
KR (1) | KR20070047246A (da) |
CN (1) | CN101022830A (da) |
AU (1) | AU2005248400A1 (da) |
CA (1) | CA2568428C (da) |
DK (1) | DK1765397T3 (da) |
ES (1) | ES2398221T3 (da) |
IL (1) | IL179565A0 (da) |
MX (1) | MXPA06013709A (da) |
PL (1) | PL1765397T3 (da) |
PT (1) | PT1765397E (da) |
RU (1) | RU2006145905A (da) |
WO (1) | WO2005116077A2 (da) |
ZA (1) | ZA200610578B (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007226856A1 (en) * | 2006-03-21 | 2007-09-27 | Michael Rynkiewicz | Methods for humanizing antibodies and humanized antibodies made thereby |
CN1919874B (zh) * | 2006-09-18 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途 |
PT2117571T (pt) * | 2006-12-08 | 2017-06-14 | Monopar Therapeutics Inc | Resumo |
US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
EP2217238B1 (en) | 2007-11-08 | 2014-03-12 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
EP3260123A1 (en) * | 2008-11-06 | 2017-12-27 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
US9885711B2 (en) | 2009-09-25 | 2018-02-06 | Xoma Technology Ltd. | Screening methods |
BR112013016107A2 (pt) | 2010-12-22 | 2017-04-04 | Ifom Fond Inst Firc Di Oncologia Molecolare | molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar |
ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
ES2765006T3 (es) | 2011-05-09 | 2020-06-05 | The Univ Of Miami | Reducción del receptor soluble de urocinasa en la circulación |
CA2842281A1 (en) | 2011-08-05 | 2013-02-14 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
EP2970383B1 (en) * | 2013-03-15 | 2021-04-21 | Board of Regents, The University of Texas System | Method of treating fibrosis |
CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
US10681506B1 (en) | 2018-04-19 | 2020-06-09 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
US10959062B1 (en) | 2018-04-19 | 2021-03-23 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
AU2019339260A1 (en) | 2018-09-10 | 2021-03-25 | Lung Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
US20220135669A1 (en) * | 2018-09-28 | 2022-05-05 | Rush University Medical Center | suPAR and Prediction and Treatment of Acute Kidney Injury |
US20220378956A1 (en) * | 2021-05-21 | 2022-12-01 | Northstar Medical Technologies Llc | Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use |
CA3221342A1 (en) * | 2021-06-11 | 2022-12-15 | Scott W. Lowe | Antigen recognizing receptors targeting upar and uses thereof |
WO2023183667A1 (en) * | 2022-03-24 | 2023-09-28 | The United States Government As Representative By The Department Of Veterans Affairs | Urokinase-type plasminogen activator receptor binding peptides and methods of use |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5532132A (en) * | 1993-09-28 | 1996-07-02 | President And Fellows Of Harvard University | Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor |
DE10117381A1 (de) * | 2001-04-06 | 2002-10-10 | Wilex Biotechnology Gmbh | Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke |
AU2003216512A1 (en) * | 2002-03-18 | 2003-10-08 | Dyax Corporation | Integrin ligand |
PT2117571T (pt) * | 2006-12-08 | 2017-06-14 | Monopar Therapeutics Inc | Resumo |
-
2005
- 2005-05-25 DK DK05754219.3T patent/DK1765397T3/da active
- 2005-05-25 JP JP2007515288A patent/JP4890449B2/ja active Active
- 2005-05-25 PT PT57542193T patent/PT1765397E/pt unknown
- 2005-05-25 EP EP05754219A patent/EP1765397B1/en active Active
- 2005-05-25 KR KR1020067027198A patent/KR20070047246A/ko not_active Application Discontinuation
- 2005-05-25 CN CNA2005800249140A patent/CN101022830A/zh active Pending
- 2005-05-25 AU AU2005248400A patent/AU2005248400A1/en not_active Abandoned
- 2005-05-25 US US11/597,689 patent/US8101726B2/en active Active
- 2005-05-25 ZA ZA200610578A patent/ZA200610578B/xx unknown
- 2005-05-25 ES ES05754219T patent/ES2398221T3/es active Active
- 2005-05-25 WO PCT/US2005/018322 patent/WO2005116077A2/en active Search and Examination
- 2005-05-25 RU RU2006145905/13A patent/RU2006145905A/ru not_active Application Discontinuation
- 2005-05-25 CA CA2568428A patent/CA2568428C/en active Active
- 2005-05-25 PL PL05754219T patent/PL1765397T3/pl unknown
- 2005-05-25 MX MXPA06013709A patent/MXPA06013709A/es active IP Right Grant
-
2006
- 2006-11-23 IL IL179565A patent/IL179565A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20070047246A (ko) | 2007-05-04 |
ES2398221T3 (es) | 2013-03-14 |
WO2005116077A2 (en) | 2005-12-08 |
ZA200610578B (en) | 2009-09-30 |
EP1765397A2 (en) | 2007-03-28 |
IL179565A0 (en) | 2007-05-15 |
CN101022830A (zh) | 2007-08-22 |
EP1765397B1 (en) | 2012-10-24 |
JP4890449B2 (ja) | 2012-03-07 |
CA2568428C (en) | 2020-12-29 |
US20090180952A1 (en) | 2009-07-16 |
AU2005248400A1 (en) | 2005-12-08 |
PT1765397E (pt) | 2013-02-04 |
MXPA06013709A (es) | 2008-01-16 |
US8101726B2 (en) | 2012-01-24 |
WO2005116077A3 (en) | 2005-12-29 |
PL1765397T3 (pl) | 2013-04-30 |
EP1765397A4 (en) | 2009-05-13 |
RU2006145905A (ru) | 2008-06-27 |
CA2568428A1 (en) | 2005-12-08 |
JP2008509086A (ja) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1765397T3 (da) | Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR) | |
NO20190202A1 (no) | Anvendelse av anti-CGRP antagonist antistoff | |
NL1027975A1 (nl) | Antilichamen tegen MAdCAM. | |
NL1032132A1 (nl) | Nieuwe MAdCAM-antilichamen. | |
NO20083147L (no) | Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse | |
EP2117571A4 (en) | UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR EPITOPE, DERIVED MONOCLONAL ANTIBODIES, AND METHODS OF USING THE SAME | |
DK1896073T3 (da) | Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
DK2390267T3 (da) | Stabile og opløselige antistoffer, der hæmmer TNF(alfa) | |
DK1945666T3 (da) | Antistoffer med forøget antistofafhængig cellulær cytotoksicitetsaktivitet, fremgangsmåder til fremstilling af disse og anvendelse heraf | |
DK2061814T3 (da) | Antistoffer og immunokonjugater og anvendelse deraf. | |
DK1723128T3 (da) | Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer | |
NO344992B1 (no) | Anti-GM-CSF antistoffer og anvendelser for disse | |
NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
NL1028927A1 (nl) | Nieuwe verbindingen. | |
NO20053101D0 (no) | Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese. | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
DE602005021959D1 (de) | Substituierte diazaspiroä4.5üdecanderivate und der | |
WO2008002472A3 (en) | Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties | |
NO20054709D0 (no) | Sammenfoyningssystem og anvendelse av dette | |
SI1960432T1 (sl) | Protitelo proci icam, ki inducira apoptozo | |
DK1866610T3 (da) | Gennemstrømningsmåler med en indgang og flere udgange | |
NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
DK1874765T3 (da) | Ureaderivater, fremgangsmåder til fremstilling af disse og anvendelser deraf |